[{"address1": "21250 Hawthorne Boulevard", "address2": "Suite 800", "city": "Torrance", "state": "CA", "zip": "90503", "country": "United States", "phone": "310 214 0065", "fax": "310 214 0075", "website": "https://www.emmausmedical.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.", "fullTimeEmployees": 54, "companyOfficers": [{"maxAge": 1, "name": "Mr. Willis C. Lee M.S.", "age": 63, "title": "Co-President, COO & Chairman of the Board", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yasushi  Nagasaki CPA, CPA", "age": 56, "title": "Chief Financial Officer", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 250000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. George  Sekulich", "age": 57, "title": "Co-President, Chief Commercial Officer & Director", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dale E. Short J.D.", "title": "Legal Consultant & Corporate Secretary", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles W. Stark Pharm.D, Pharm.D.", "age": 68, "title": "Senior Vice President of Medical Affairs, Clinical, Regulatory", "yearBorn": 1955, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kurt H. Kruger M.B.A., M.S.", "age": 68, "title": "Consultant", "yearBorn": 1955, "fiscalYear": 2022, "totalPay": 300020, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.08, "open": 0.1, "dayLow": 0.09, "dayHigh": 0.125, "regularMarketPreviousClose": 0.08, "regularMarketOpen": 0.1, "regularMarketDayLow": 0.09, "regularMarketDayHigh": 0.125, "beta": 1.741, "forwardPE": -1.4285715, "volume": 128333, "regularMarketVolume": 128333, "averageVolume": 43648, "averageVolume10days": 38710, "averageDailyVolume10Day": 38710, "bidSize": 1800, "askSize": 1300, "marketCap": 5363760, "fiftyTwoWeekLow": 0.051, "fiftyTwoWeekHigh": 0.515, "priceToSalesTrailing12Months": 0.18846662, "fiftyDayAverage": 0.10704, "twoHundredDayAverage": 0.194555, "currency": "USD", "enterpriseValue": 37943756, "profitMargins": -0.16662, "floatShares": 29124655, "sharesOutstanding": 53637600, "sharesShort": 41217, "sharesShortPriorMonth": 33642, "sharesShortPreviousMonthDate": 1561680000, "dateShortInterest": 1565827200, "sharesPercentSharesOut": 0.00090000004, "heldPercentInsiders": 0.51568, "heldPercentInstitutions": 0.00187, "shortRatio": 0.48, "shortPercentOfFloat": 0.00090000004, "impliedSharesOutstanding": 53637600, "bookValue": -0.677, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -4742000, "trailingEps": -0.08, "forwardEps": -0.07, "lastSplitFactor": "1:6", "lastSplitDate": 1563408000, "enterpriseToRevenue": 1.333, "enterpriseToEbitda": 47.077, "52WeekChange": -0.78947365, "SandP52WeekChange": 0.20484698, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "EMMA", "underlyingSymbol": "EMMA", "shortName": "EMMAUS LIFE SCIENCES INC NEW", "longName": "Emmaus Life Sciences, Inc.", "firstTradeDateEpochUtc": 957879000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e6bbb707-7f5d-32e4-96ee-b7518dfffbab", "messageBoardId": "finmb_39585025", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.1, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 1505000, "totalCashPerShare": 0.028, "ebitda": 806000, "totalDebt": 34085000, "quickRatio": 0.1, "currentRatio": 0.152, "totalRevenue": 28460000, "revenuePerShare": 0.55, "returnOnAssets": 0.01069, "freeCashflow": 12529750, "operatingCashflow": -862000, "revenueGrowth": 0.016, "grossMargins": 0.93689, "ebitdaMargins": 0.02832, "operatingMargins": 0.00478, "financialCurrency": "USD", "trailingPegRatio": null}]